Common Contracts
2 similar Clinical Trial Collaboration Agreement contracts by Nektar Therapeutics
EX-10.1 2 nktr-ex101_8.htm EX-10.1 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 CLINICAL TRIAL COLLABORATION AGREEMENTClinical Trial Collaboration Agreement • May 5th, 2020 • New York
This Clinical Trial Collaboration Agreement (the “Agreement”) is made and entered into effective as of September 21, 2016 (the “Effective Date”) by and between Nektar Therapeutics, a Delaware corporation, headquartered at 455 Mission Bay Boulevard South, San Francisco, CA 94158 (“Nektar”), and Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”). Nektar and BMS may be referred to herein individually as a “Party,” or collectively as the “Parties.”
CLINICAL TRIAL COLLABORATION AGREEMENTClinical Trial Collaboration Agreement • November 4th, 2016 • Nektar Therapeutics • Pharmaceutical preparations • New York
This Clinical Trial Collaboration Agreement (the “Agreement”) is made and entered into effective as of September 21, 2016 (the “Effective Date”) by and between Nektar Therapeutics, a Delaware corporation, headquartered at 455 Mission Bay Boulevard South, San Francisco, CA 94158 (“Nektar”), and Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”). Nektar and BMS may be referred to herein individually as a “Party,” or collectively as the “Parties.”
